



# Sim & McBurney

Patent and Trade Mark Agents

Please Quote  
Our ref. 1038-1268 MIS/ac

Your ref.

Writer's Ext. 239

E-mail: [mistewart@sim-mcburney.com](mailto:mistewart@sim-mcburney.com)

April 26, 2004

## VIA COURIER

Mail Stop D D  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sirs:

**RE: U.S. Patent Application No. 10/663,722**

**Filing Date: September 17, 2003**

**Applicant: George A. Cates et al.**

**Title: MULTIVALENT IMMUNIGENIC COMPOSITION CONTAINING  
RSV SUBUNIT COMPOSITION AND INFLUENZA VIRUS  
PREPARATION**

Please find enclosed an Information Disclosure Statement and copies of the references listed therein with respect to each of the references cited in the specification, in the International Search Report received on the corresponding International application and in prior U.S. application No. 09/213,770.

Respectfully submitted,

Michael I. Stewart  
Registration No. 24,973

M.I. Stewart/ac  
Enclosures

330 University Avenue  
6th floor  
Toronto, Canada  
M5G 1R7

Telephone (416) 595-1155  
Fax (416) 595-1163


MICHAEL I. STEWART  
ROGER T. HUGHES, Q.C.  
TONI POLSON ASHTON  
JOHN H. WOODLEY  
KENNETH D. MCKAY  
TIMOTHY M. LOWMAN  
STEPHEN M. LANE  
ARTHUR B. RENAUD  
STEPHEN J. PERRY  
PATRICIA A. RAE  
DAVID A. RUSTON  
BARBARA J. MURCHIE  
L.E. TRENT HORNE  
LOLA A. BARTOSZEWCZ  
KAMLEH J. NICOLA

GEOFFREY B.C. DE KLEINE  
KIMBERLY A. MCMANUS  
WENDY M. NOSS  
MATTHEW D. POWELL  
REBECCA M. EAGEN  
COBY A.B. SCHNEIDER

SENIOR CONSULTANT  
PETER W. MCBURNAY

TECHNICAL ASSISTANTS  
MICHAEL S. COLUCCI, Ph.D.  
ANDREW R.O. JONES, B.A., LL.B.  
MARCO M. CLEMENTONI, B. MATH.  
KENNETH M. T. MURPHY, B.Sc.E.  
JEILAH Y. CHAN, B.Sc., LL.B.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 1038-1268 MIS:ac	SERIAL NO. 10/663,722
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT GEORGE A. CATES et al	
		FILING DATE September 17, 2003	GROUP 1642



## U.S. PATENT DOCUMENTS

*INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCL.	FILING DATE
	5,494,673	Feb. 27/96				
	5,612,037	Mar. 18/97				
	5,911,998	Jun. 15/99				
	6,020,182	Feb. 1/00				

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCL.	TRANSLATION YES      NO
	WO 95/02628	Jan. 26/95				
	WO 96/33738	Oct. 31/96				
	WO 95/34308	Dec. 21/95				
	WO 95/34323	Dec. 21/95				
	WO 98/02457	Jan. 22/98				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1. Glezen, W.P., et al. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level (1981). Vol. 98, pp. 708-715.
	2. Chanock, R.M., Serious respiratory track disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization (1992) Vol. 90, pp.137-142.
	3. Martin, A.J. et al. Epidemiology of respiratory viral infection among paediatric inpatients over six-year period in north-east England (1978), pp. 1035-1038.
	4. Robbins, A., and Freeman, P. Obstacles to developing vaccines for the third world. (1988) 259, 126-133.
	5. Glezen, W.P., et al. Risk of primary infection and reinfection with respiratory syncytial virus. (1986) 140, pp. 543-546.
	6. Katz, S.L. Prospects for immunizing against respiratory syncytial virus. Vol. 1. Washington: National Academic Press. (1985) pp. 397-409.
	7. Wertz, G.W., Sullender, W.M. Approaches to immunization against respiratory syncytial virus (1992) Vol. 20, pp.151-176.
	8. McIntosh, K. and Chanock, R.M. Respiratory syncytial virus. (1990) pp. 1045-1075.
	9. Murry AR, Dowell SF, 1997. Respiratory syncytial virus: not just for kids. Hosp. Pract. (Off Ed) 1997 Jul. 15; 32(7): 87-8, 91-4.

EXAMINER:

DATE CONSIDERED:

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 1038-1268 MIS:ac	SERIAL NO. 10/663,772
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT GEORGE A. CATES et al	
		FILING DATE September 17, 2003	GROUP 1642

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
		10. Mlinaric-Galinovic G, Falsey AR, Walsh EE, 1996. Respiratory syncytial virus infection in the elderly. 1996. 15, pp. 777-781	
		11. Collins, P., et al. Respiratory syncytial Virus. (1996) pp.1313-1351.	
		12. Walsh, E.E., Hall, Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection. (1987) Vol. 155, pp.1198-1204.	
		13. Walsh, E.E., Hruska, J. Monoclonal antibodies to respiratory syncytial virus proteins: Identification of the fusion protein. (1983) Vol. 47, pp. 171-177.	
		14. Levine, S., et al. Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus (1987) Vol. 69, pp. 2521-2524.	
		15. Anderson, L.J., et al. Antigenic Characterization of respiratory syncytial virus strains with monoclonal antibodies (1985), Vol. 151, pp.626-633.	
		16. Johnson, P.R., et al. Antigenic Relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B.... (1987) Vol. 61 (10), pp.3163-3166.	
		17. Cherrie, A.H., et al. Human cytotoxic T cell stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus. (1992) J. Virology 66, 2102-2110.	
		18. Kim, H.W., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine (1969) Vol 89, 422-434.	
		19. Friedewald, W.T., et al. Low-temperature-grown RS virus in adult volunteers. (1968) Vol. 204, pp. 142-146.	
		20. Walsh, E.E., et al. Purification and characterization of the respiratory syncytial virus fusion protein. (1985) Vol. 66, pp. 409-415.	
		21. Walsh, E.E., et al. Purification and characterization of GP90, One of the envelope glycoproteins of respiratory syncytial virus. (1984) Vol. 65, 761-766.	
		22. Routledge, E.G., The purification of four respiratory syncytial virus proteins and their evaluation as protective agents against experimental infection in BALB/c mice. (1988) Vol. 69, 293-303.	
		23. Fulginiti, V.A., et al. Respiratory Virus Immunization. (1969) Vol. 89 (4), pp. 435-448.	
		24. Chin, J., et al. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population (1969) Vol. 89 (4), pp. 449-463.	
		25. Kapikian, et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) .... (1969) Vol. 89 (4), pp. 405-421.	
		26. Kim, H.W., et al. Clinical and Immunological response of infants and children to administration of low-temperature adapted respiratory sysncytial virus. (1971), Vol 48, pp. 745-755.	
		27. Wright, P.F., et al. Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children (1982) Vol. 37 (1), pp. 397-400.	
		28. Wright, P.F., et al. Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants.(1976) Vol. 88, pp.931-936.	
EXAMINER:		DATE CONSIDERED:	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 1038-1268 MIS:ac	SERIAL NO. 10-663,722
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT GEORGE A. CATES et al	
		FILING DATE September 17, 2003	GROUP 1642

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	29. Belshe, R.B., Parenteral administration of live respiratory syncytial virus vaccine; results of a field trial. (1982) Vol. 145, pp 311-319.
	30. Murphy, B.R., et al. Dissociation between serum neutralizing and glycoprotein antibody response of infants and children who received inactivated respiratory syncytial virus vaccine(1986), 24(2), 197-202.
	31. Connors, M., et al. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia -RSV recombinants or RSV. (1992) Vol. 10, pp. 475-484.
	32. Prince, G.A., et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. (1986) Vol. 57 (3), pp. 721-728.
	33. Piedra, P.A., et al. Immune response to experimentally induced infection with respiratory syncytial virus: Possible role in the development of pulmonary disease. (1989) Vol. 70, pp. 325-333.
	34. Payne G.L., et al. Vaccine Vol. 16. pp. 92-98 1998.
	35. Fattom Al et al. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. (1999) Vol. 17 pp. 126-133
	36. Ambrosch F., et al., Combined vaccination against yellow fever a comparative trial. 1994 Vol. 12 pp. 625-628.
	37. Frey Sharon et al. Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/Hepatitis B Vaccine 1999; 180 pp. 2018-2022.
	38. Insel, A. Richard., Potential alterations in Immnogenicity by Combining or Simultaneously Administering Vaccine Components. pp. 35-47.
	39. Plotkin A.S. et al. Vaccines. Third Edition pp. 508-530.
EXAMINER:	DATE CONSIDERED:

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.